
Benjamin Gilbert Neel MD
Director, Laura and Isaac Perlmutter Cancer Center
Join to view full profile
77 Avenue Louis Pasteur# NrbBoston, MA 02115
Phone+1 617-667-2823
Fax+1 212-263-9190
Dr. Neel is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1983 - 1987
Weill Cornell MedicineClass of 1983
Certifications & Licensure
MA State Medical License 1984 - 2028
Publications & Presentations
PubMed
- Author Correction: Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma.Shuang Zhang, Igor Dolgalev, Tao Zhang, Hao Ran, Douglas A Levine
Nature Communications. 2026-07-23 - Pan-cancer proteogenomic interrogation of the ubiquitin-proteasome system.Tania J González-Robles, Maha Khan, Paul Sastourné, Marisa Triola, Hua Zhou
Cell Death and Differentiation. 2026-07-19 - UbiDash: A UPS proteomic atlas for tissue-aware degrader design.Tania J González-Robles, Paul Sastourné, Marisa Triola, Maha Khan, Áron Bartha
Cell Death and Differentiation. 2026-07-10
Journal Articles
- The Gp1ba-Cre Transgenic Mouse: A New Model to Delineate Platelet and Leukocyte FunctionsBenjamin Neel, MD, Blood
Press Mentions
NYU Grossman Rescinds Program Acceptances After Losing Federal GrantMay 14th, 2025
MSK Research Highlights, January 17, 2025January 17th, 2025
NYU Langone Health’s Perlmutter Cancer Center Continues to Grow in Brooklyn, Provide Care to Diverse PopulationsApril 5th, 2023
Grant Support
- SHP2 Signaling from Molecule to MouseNEW YORK UNIVERSITY SCHOOL OF MEDICINE2026–2031
- Exploiting synthetic lethality to enhance KRAS inhibitor therapy of cancerNEW YORK UNIVERSITY SCHOOL OF MEDICINE2025–2027
- Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1NEW YORK UNIVERSITY SCHOOL OF MEDICINE2022–2026
- Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1NEW YORK UNIVERSITY SCHOOL OF MEDICINE2022–2026
- New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian CarcinomaNEW YORK UNIVERSITY SCHOOL OF MEDICINE2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









